Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $4,628,250.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 45,000 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00. Following the completion of the transaction, the chief executive officer directly owned 813,209 shares of the company’s stock, valued at approximately $83,638,545.65. The trade was a 5.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00.

BioNTech Stock Down 1.8%

Shares of BNTX opened at $96.40 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00. The stock has a market capitalization of $24.38 billion, a price-to-earnings ratio of -12.31 and a beta of 1.29. The stock has a fifty day moving average of $97.00 and a 200-day moving average of $95.37.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company’s revenue was down 59.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.60) EPS. As a group, sell-side analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently bought and sold shares of the company. Monaco Asset Management SAM bought a new stake in shares of BioNTech in the 4th quarter valued at $1,594,000. Hsbc Holdings PLC acquired a new stake in BioNTech in the fourth quarter worth $4,969,000. Bank of America Corp DE grew its holdings in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after purchasing an additional 166,432 shares during the period. BNP Paribas Financial Markets increased its stake in BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after purchasing an additional 474,796 shares in the last quarter. Finally, Amundi increased its stake in BioNTech by 24.5% in the first quarter. Amundi now owns 129,513 shares of the company’s stock valued at $11,511,000 after purchasing an additional 25,506 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on BNTX shares. BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $128.00 to $105.00 in a research report on Tuesday. Canaccord Genuity Group dropped their price target on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Monday, August 31st. UBS Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $117.00 to $135.00 in a report on Wednesday, May 27th. Citigroup decreased their price objective on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.